18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab

Naghmehossadat Eshghi, Tamara F. Lundeen, Lea Mackinnon, Ryan Avery, Phillip H Kuo

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.

LanguageEnglish (US)
Pagese142-e144
JournalClinical Nuclear Medicine
Volume43
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Merkel Cell Carcinoma
Fluorodeoxyglucose F18
Cell Death
Neoplasm Metastasis
Ligands
Active Immunotherapy
Liver
Dissection
Comorbidity
Radiotherapy
Drug Therapy
avelumab

Keywords

  • avelumab
  • FDG PET/CT
  • immunotherapy
  • Merkel cell carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. / Eshghi, Naghmehossadat; Lundeen, Tamara F.; Mackinnon, Lea; Avery, Ryan; Kuo, Phillip H.

In: Clinical Nuclear Medicine, Vol. 43, No. 5, 01.05.2018, p. e142-e144.

Research output: Contribution to journalArticle

Eshghi, Naghmehossadat ; Lundeen, Tamara F. ; Mackinnon, Lea ; Avery, Ryan ; Kuo, Phillip H. / 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab. In: Clinical Nuclear Medicine. 2018 ; Vol. 43, No. 5. pp. e142-e144.
@article{5ca67ded986a423d8dbcc581cc09ac20,
title = "18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab",
abstract = "An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.",
keywords = "avelumab, FDG PET/CT, immunotherapy, Merkel cell carcinoma",
author = "Naghmehossadat Eshghi and Lundeen, {Tamara F.} and Lea Mackinnon and Ryan Avery and Kuo, {Phillip H}",
year = "2018",
month = "5",
day = "1",
doi = "10.1097/RLU.0000000000002051",
language = "English (US)",
volume = "43",
pages = "e142--e144",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab

AU - Eshghi, Naghmehossadat

AU - Lundeen, Tamara F.

AU - Mackinnon, Lea

AU - Avery, Ryan

AU - Kuo, Phillip H

PY - 2018/5/1

Y1 - 2018/5/1

N2 - An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.

AB - An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.

KW - avelumab

KW - FDG PET/CT

KW - immunotherapy

KW - Merkel cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85045696297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045696297&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002051

DO - 10.1097/RLU.0000000000002051

M3 - Article

VL - 43

SP - e142-e144

JO - Clinical Nuclear Medicine

T2 - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 5

ER -